{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117166","form_type":"8-K","ticker":"XWEL","cik":"0001410428","company_name":"XWELL, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.506910+00:00","generated_at":"2026-06-21T22:39:34.423872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XWELL Q3 revenue $10.7M (down 60%), net loss $7.2M vs profit $5.6M","bullets":["Revenue $10.7M, down 60% from $26.8M; loss from operations $7.65M vs income $7.1M in Q3 2021.","Net loss attributable to common shareholders $7.2M vs net income $5.6M in prior year; Adjusted EBITDA loss $4.56M.","Closed five unprofitable XpresCheck locations in Q3; plans to close seven more in Q4; two XpresCheck sites and five biosurveillance stations expected for 2023.","Cash and equivalents $49.4M, no debt; repurchased 11.0M shares at avg $1.03 in Q3 for $11.4M.","Awarded new CDC/Ginkgo biosurveillance contract with potential value up to $61M based on options."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117166","json":"https://secwatch.observer/filing/0001104659-22-117166.json","markdown":"https://secwatch.observer/filing/0001104659-22-117166.md","text":"https://secwatch.observer/filing/0001104659-22-117166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410428/000110465922117166/0001104659-22-117166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410428/000110465922117166/tm2230190d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:39:34.423872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1d53b6c9b12b49015e1dd2549b8bb6f68e9780f","claim":"XWELL, Inc. reported financial results for the third quarter ending September 30, 2022.","evidence_excerpt":"NEW YORK, November 10, 2022 -- XWELL, Inc. (Nasdaq: XWEL), a leading global health and wellness holding company, today reported results for the third quarter ending September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410428/000110465922117166/0001104659-22-117166-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ending September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}